Immunophenotyping has become a critical tool in the management of hematological malignancies including Multiple Myeloma (MM) with an increasingly importance with diagnosis and monitoring of Minimal Residual Disease (MRD). Here, we review th...
Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower... J Flores-Montero,LS Flores,B Paiva,... - 《...
Multiple myeloma (MM) is a neoplasm of plasma cells that secrete patient specific monoclonal immunoglobulins. A recognized problem in MM treatment is the early recognition of minimal residual disease (MRD), the major cause of relapse. Current MRD detection methods (multiparameter flow cytometry and ...
At present, immunophenotyping is mandatory for the diagnosis and monitoring of acute leukemias and chronic lymphoproliferative disorders.1-4 By contrast, in multiple myeloma, the use of multiparametric flow cytometry in many clinical diagnostic laboratories is currently restricted to clinical research studies...
The consortium is a subset of the International Myeloma Working Group, the research arm of the IMF. Q: How will this group create tests that are sensitive enough to check for MRD zero? A: There are two types of tests that we use on these patients now. One is automated flow cytometr...
With the advent of multiparameter flow cytometry (FC) it became possible simultaneously analyze normal and malignant plasma cells (PC) in multiple myeloma (MM) patients. There is some data that residual normal bone marrow plasma cells (nBMPC) is of prog- nostic significance in plasma cells ...
PURPOSE OF REVIEW: Although the input of multiparameter flow cytometry (MFC) into the clinical management of multiple myeloma patients has faced some reluctance, continuously growing evidence supports the utility of MFC in this disease. RECENT FINDINGS: MFC immunophenotyping of bone marrow and periphera...
Evolving Role of MRD Status in Multiple Myeloma The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meetin...
and light chain multiple myeloma (LCMM) who achieved a very good partial response (VGPR) or better. Multicolour flow cytometry was used to assess the depth of response. LCMM patients with sCR had significantly lower measurable residual disease (MRD) levels than those with CR (median MRD: 7....
The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma ...